Ulcerative Colitis

SAN DIEGO — Patients with inflammatory bowel disease experienced reduced symptom frequency and severity after a third SARS-CoV-2 mRNA vaccine compared with after a second, according to data presented at Digestive Disease Week 2022.

SAN DIEGO — Patients with ulcerative colitis who responded to mirikizumab at 12 weeks achieved and maintained clinical remission and improved bowel urgency severity at 1 year in the phase 3 LUCENT-2 study.

SAN DIEGO — Among ulcerative colitis patients in endoscopic remission, histologic inflammation increased the risk for loss of remission, according to a presentation at Digestive Disease Week 2022.

SAN DIEGO — In a Healio video exclusive, Marla C. Dubinsky, MD, discusses results from the ELEVATE UC trials, in which once daily etrasimod induced clinical remission in patients with ulcerative colitis.

SAN DIEGO — Seroconversion rates and antibody response significantly increased after a third dose of SARS-CoV-2 vaccine in patients with inflammatory bowel disease, according to a presenter at Digestive Disease Week 2022.

SAN DIEGO — Anxiety left unaddressed in the context of inflammatory bowel disease care “will impact the disease course and outcomes,” according to a presenter at Digestive Disease Week 2022.

SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory bowel disease therapy at an older age.

SAN DIEGO — Older patients with inflammatory bowel disease who were treated with biologics exhibited a lower incidence of dementia compared with those never treated with biologics, according to data presented at Digestive Disease Week 2022.

SAN DIEGO — Obesity was not linked to hospitalization, surgery or serious infection among a subset of biologic-treated patients with inflammatory bowel disease, according to research presented at Digestive Disease Week 2022.

SAN DIEGO — Paternal exposure to the majority of therapies for inflammatory bowel disease did not increase the risk for adverse neonatal outcomes, according to data from a small patient subset presented at Digestive Disease Week 2022.